Press releases View full list

July 30, 2014

Invitae and Nanopharmacia Announce Partnership to Make Reliable, Fast and Affordable Hereditary Cancer Genetic Testing Broadly Available in Mexico

-- Partnership Expands Invitae’s Global Presence into Mexico, Costa Rica, & Panama --

SAN FRANCISCO and MEXICO CITY― July 30, 2014 ― Invitae Corporation, a genetic information company, and Nanopharmacia, the leading oncology molecular test provider in Mexico, today announced an exclusive partnership to make Invitae’s genetic tests for the management of hereditary cancers broadly available throughout Mexico.  In addition, the partnership includes access on a non-exclusive basis in Costa Rica and Panama. 

Nanopharmacia will offer Invitae’s hereditary cancer panels and BRCA1/BRCA2 offering to a  wide network of onco-geneticists and medical and surgical oncologists. Invitae’s oncology offering  includes the following:

  • Single gene BRCA1 and BRCA2, including full gene sequencing and deletion/duplication analysis
  • High-risk hereditary breast cancer panel (6 genes)
  • Women’s hereditary cancer panel (18 genes associated with hereditary breast, ovarian and endometrial cancer)
  • Hereditary cancer syndromes panel (29 genes)
  • Hereditary Pancreatic Cancer Panel (17 genes)
  • Additional hereditary cancer panels are available, including testing for Lynch Syndrome and colon cancers

“This partnership with Nanopharmacia provides clinicians and their patients with reliable, fast and affordable genetic testing while also advancing our mission to make genetic testing more accessible to patients in need around the globe,” said Lisa Alderson of Invitae.  “Nanopharmacia has been a leader in Mexico in embracing molecular medicine as a cornerstone to guide patient care, and we are proud to work with such a dedicated and well-respected organization to help improve the health of patients.” 

The partnership includes access for advanced next generation genetic testing in Mexico through a network of approximately 800 oncology professionals  in  Mexico, as well as in Costa Rica and Panama. 

“Genetic information is critical to improving the care of patients with hereditary cancers, and we believe that the adoption of Invitae’s tests will significantly help patients in Mexico and other territories we service,” said Horacio Astudillo, chairman of the board at Nanopharmacia. “Nanopharmacia is committed to bringing high-quality innovation to help patients with cancer.”

About Nanopharmacia

Nanopharmacia Diagnostica is an operational unit that performs molecular tests of high and low complexity for the personalized diagnosis of cancer and other diseases, in order to support patients in México and Latin America. Nanopharmacia is composed of a group of experts in the biomolecular field, specializing in cancer genomics and molecular oncology. Nanopharmacia works with the highest quality standards, certified by ISO-9001:2008, Applus and RENIECYT. Focusing its business in life and health, through its division Life Science Solutions, Nanopharmacia provides solutions for the pharmaceutic industry, hospitals, biotechnological laboratories and related industries.

About Invitae Corporation

Invitae is a genetic information company whose mission is to bring genetic information into routine medical practice to improve the quality of healthcare for billions of people.  Specializing in genetic diagnostics for hereditary disorders, Invitae is aggregating the world’s genetic tests into a single service with better quality, faster turnaround time, and a lower price than most single-gene diagnostic tests today.  Invitae has raised $87 million from investors, including Thomas McNerney Partners, Casdin Capital, Genesys Capital, Genomic Health, Inc. (NASDAQ: GHDX), and Redmile Group.  For further information, please visit


Katherine Stueland

Nanopharmacia Diagnóstica SA de CV:
01 800 910 6266
+55 52 64 28 15

Investor Toolkit

Feature Presentation

Email Alerts

Sign up to receive Invitae financial information by email.
Email Address: *

Enter the code shown above.

Investor Contact

1400 16th St.
San Francisco, CA, 94103